Pfizer and BioNTech said Tuesday that they have submitted initial data to the Food and Drug Administration from their vaccine trial on children between 5 and 11 years old.
The drugmakers said their trial, which included 2,268 participants from that age group, yielded “positive topline results.” The companies said their coronavirus vaccine has “demonstrated a favorable safety profile” among young participants and “elicited robust neutralizing antibody responses using a two-dose regimen.”
Covidpedia Labs offers public health information on the COVID 19 pandemic for your general knowledge. This information does not replace written law or professional medical advice, diagnosis, or treatment. It is intended to raise awareness on COVID-19 for public use and consumption. If you have questions from the information you have read on this site regarding a medical condition, access to medicine and/or vaccines, always seek the professional advice of a doctor or other qualified health professionals. All copyrighted content is labeled. If you’d like to share copyrighted content, contact the owner of that material.
